Edition:
United Kingdom

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

5.50EUR
18 Apr 2019
Change (% chg)

€-0.11 (-1.96%)
Prev Close
€5.61
Open
€5.64
Day's High
€5.64
Day's Low
€5.36
Volume
156,982
Avg. Vol
108,873
52-wk High
€9.38
52-wk Low
€4.36

Latest Key Developments (Source: Significant Developments)

Nicox Q1 Net Revenue Up At 0.43 Million Euros
Thursday, 18 Apr 2019 

April 18 (Reuters) - NICOX SA ::REG-NICOX FIRST QUARTER 2019 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.THE TOTAL NUMBER OF PRESCRIPTIONS FOR VYZULTA IN THE U.S. IN THE FIRST QUARTER OF 2019 INCREASED BY 18% COMPARED TO Q4 20181 AND BY 360% COMPARED TO THE FIRST QUARTER 2018.AS OF MARCH 31, 2019, THE NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF €23.5 MILLION AS COMPARED WITH €22.0 MILLION AT DECEMBER 30, 2018.ENROLLMENT HAS NOW REACHED OVER 85% IN NCX 470 GLAUCOMA CLINICAL TRIAL, AND BOTH THIS AND NCX 4251 BLEPHARITIS TRIAL SHOULD GENERATE TOPLINE RESULTS IN Q4 OF THIS YEAR.NET REVENUE FOR THE FIRST QUARTER OF 2019 WAS €0.430 MILLION VERSUS €0.075 MILLION IN THE FIRST QUARTER OF 2018..WE EXPECT OUR RECURRENT REVENUES TO RAMP UP AS BAUSCH + LOMB PROGRESSES THE INTERNATIONAL ROLLOUT OF VYZULTA, AND WITH THE LAUNCH BY EYEVANCE OF ZERVIATE IN THE U.S - CEO.  Full Article

Nicox Initiates Phase 2 Trial Of NCX 4251 In Blepharitis
Tuesday, 19 Mar 2019 

March 19 (Reuters) - NICOX SA ::INITIATES PHASE 2 TRIAL OF NCX 4251 IN BLEPHARITIS.TOP-LINE RESULTS EXPECTED IN Q4 2019.TARGETS ESTIMATED $500+ MILLION U.S. BLEPHARITIS MARKET.TRIAL TO RANDOMIZE 30 BLEPHARITIS PATIENTS IN CLINICAL SITES ACROSS U.S..  Full Article

Nicox Signs Deal For Zerviate In China For Up To EUR 17 Mln In Milestone Payments, Royalties
Friday, 15 Mar 2019 

March 15 (Reuters) - Nicox SA ::REG-NICOX SIGNS AGREEMENT FOR ZERVIATE IN CHINA FOR UP TO €17 MILLION IN MILESTONE PAYMENTS PLUS ROYALTIES.MAY POTENTIALLY RECEIVE DEVELOPMENT AND SALES MILESTONES OF UP EUR 17 MILLION TOGETHER WITH ROYALTIES OF BETWEEN 5% AND 9% ON SALES OF ZERVIATE.ALONG WITH OCUMENSION THERAPEUTICS ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NICOX'S PRODUCT ZERVIATE(TM )(CETIRIZINE OPHTHALMIC SOLUTION).OCUMENSION WILL RECEIVE EXCLUSIVE RIGHTS FOR AGREED TERRITORY TO DEVELOP AND COMMERCIALIZE ZERVIATE.  Full Article

Nicox FY Loss Widens To EUR 18.4 Million
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Nicox SA ::NET REVENUE FOR 12 MONTHS TO DECEMBER 2018 WAS EUR 4.0 MILLION, INCREASED BY 74%.AS OF DECEMBER 31, 2018, NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF EUR 22.0 MILLION AS COMPARED WITH EUR 41.4 MILLION AT DECEMBER 31, 2017.FY LOSS FOR THE PERIOD EUR 18.4 MILLION VERSUS LOSS OF EUR 3.6 MILLION YEAR AGO.FY ESTIMATED OPERATING LOSS EUR 20.7 MILLION VERSUS LOSS OF EUR 18.5 MILLION YEAR AGO.NCX 470: TOP-LINE RESULTS FROM PHASE 2 CLINICAL STUDY FOR LOWERING OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION EXPECTED IN Q4 2019.AS OF DEC 31, 2018, GROUP HAD CASH AND CASH EQUIVALENTS OF €22.0 MILLION AS COMPARED WITH €41.4 MILLION AT DEC 31, 2017.COMMERCIAL LAUNCH OF ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% IN U.S. BY OUR U.S. PARTNER EYEVANCE PHARMACEUTICALS EXPECTED IN SUMMER 2019.  Full Article

Nicox Enters Into Bond Financing For Up To 20 Million Euros From Kreos Capital
Friday, 25 Jan 2019 

Jan 25 (Reuters) - NICOX SA ::REG-NICOX EXTENDS CASH RUNWAY BEYOND 2020 WITH BOND FINANCING FROM KREOS CAPITAL OF UP TO €20 MILLION.EUR 8 MILLION DRAWN DOWN IMMEDIATELY; TWO ADDITIONAL TRANCHES OF EUR 7 MILLION AND EUR 5 MILLION AVAILABLE IN FUTURE TO BE DRAWN DOWN AT NICOX'S DISCRETION.INCLUDING CURRENT CASH ON HAND AND EXPECTED REVENUES, USE OF FULL BOND FINANCING COULD EXTEND NICOX'S CASH RUNWAY BEYOND 2020.AS PART OF THIS FINANCING, KREOS WILL RECEIVE 308,848 WARRANTS FOR 308,848 NICOX SHARES.FINANCING OF UP TO EUR 20 MILLION, STRUCTURED AS BONDS, CONSIST OF 3 TRANCHES.FIRST TRANCHE OF EUR 8 MILLION WILL BE DRAWN DOWN ON OR ABOUT FEBRUARY 1(ST ), 2019.COMPANY HAS OPTION, BUT NO OBLIGATION, TO DRAW DOWN A FURTHER MAXIMUM AMOUNT OF EUR 7 MILLION ON AUGUST 1(ST), 2019.  Full Article

Nicox End-Dec. Cash And Cash Equivalents Of EUR 22.0 Million
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - NICOX SA ::REG-NICOX FOURTH QUARTER 2018 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.NET REVENUE FOR YEAR 2018 OF EUR 4.0 MILLION.AS OF DECEMBER 31, 2018, NICOX GROUP HAD CASH AND CASH EQUIVALENTS OF EUR 22.0 MILLION.NICOX WILL NO LONGER RECEIVE $1 MILLION MILESTONE PAYMENT ASSOCIATED WITH DELIVERY OF COMMERCIAL PRODUCT TO EYEVANCE BUT REMAINS ELIGIBLE FOR UP TO $3 MILLION OF A POTENTIAL FUTURE MILESTONE PAYMENT.  Full Article

Vyzulta Approved In Canada By Nicox's Partner
Friday, 4 Jan 2019 

Jan 4 (Reuters) - NICOX SA ::VYZULTA APPROVED IN CANADA BY NICOX'S PARTNER.VYZULTA (TM)IS INDICATED FOR REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION.NICOX RECEIVES INCREASING TIERED NET ROYALTIES OF 6% TO 12% ON GLOBAL SALES OF VYZULTA (TM).NICOX RECEIVES UP TO $150 MILLION IN NET SALES MILESTONES LINKED TO GLOBAL SALES.  Full Article

Nicox Enters Into Collaboration With Novaliq
Friday, 21 Dec 2018 

Dec 21 (Reuters) - NICOX SA ::FOCUSES RESEARCH ACTIVITIES ON NOVEL NO-DONATING PDE5 INHIBITORS FOR GLAUCOMA AND ENTERS INTO COLLABORATION WITH NOVALIQ.COLLABORATION WITH NOVALIQ TO ACCESS NOVEL FORMULATION TECHNOLOGY FOR THESE NEW COMPOUNDS.ENCOURAGING PRECLINICAL EFFICACY DATA ON NO-DONATING PDE5 INHIBITORS.FOCUSING OF RESEARCH ACTIVITIES ON MOST PROMISING NEW PHARMACOLOGIC CLASSES.EXPECTS TO BE ABLE TO ANNOUNCE A PRECLINICAL CANDIDATE FROM ONE OF THESE PROGRAMS IN THE NEXT 18 MONTHS.  Full Article

Nicox Reports Cash And Cash Equivalents Of 25.7 Million Euros at Sept 30
Wednesday, 17 Oct 2018 

Oct 17 (Reuters) - NICOX SA ::REG-NICOX THIRD QUARTER 2018 BUSINESS UPDATE AND FINANCIAL HIGHLIGHTS.NCX 470 PHASE 2 CLINICAL STUDY INITIATED IN Q3 2018.NET REVENUE IN Q3 FROM VYZULTA SALES INCREASED BY 66% COMPARED TO Q2 2018.AS OF SEPTEMBER 30, 2018, CO HAD CASH AND CASH EQUIVALENTS OF €25.7 MILLION AS COMPARED WITH €32.7 MILLION AT JUNE 30.NET REVENUE FOR THE THIRD QUARTER OF 2018 WAS $0.438 MILLION.  Full Article

Nicox And Fera Pharmaceuticals Amend Their Agreement For Naproxcinod
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - NICOX SA ::REG-NICOX AND FERA PHARMACEUTICALS TO FOCUS ON A RARE DISEASE INDICATION FOR NAPROXCINOD.POTENTIAL SALES-BASED MILESTONE INCREASED TO $40 MILLION IF ANNUAL SALES REACH $1 BILLION.  Full Article

Nicox teams up with Chinese firm to develop and sell glaucoma drug

PARIS French ophthalmology company Nicox and Chinese firm Ocumension Therapeutics said on Monday they had signed an exclusive licence agreement to develop and sell a yet-to-be approved Nicox drug to treat glaucoma in China.